Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

Verona Pharma PLC (NASDAQ:VRNA) shares have reached an all-time high, touching a price level of $62.09. According to ...

Canaccord Genuity maintained a Buy rating on Verona Pharma (NASDAQ:VRNA) while significantly increasing the price target to $72.00 from the previous $44.00. According to InvestingPro data, analyst ...

Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $72 from $44 and keeps a Buy rating on the shares. The firm believes the ...

Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients ...

Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn ...

For instance, the approval of Verona Pharma’s Ohtuvayre by the U.S. Food and Drug Administration (FDA) provided a much-needed non-steroid inhaled treatment option for patients with chronic obstructive ...

Verona's stock could build on its gains from last year depending on how well the rollout of Ohtuvayre goes. And if the company is able to shrink its losses (they have totaled $154 million over the ...

First shared at a recent Japanese Society of Digital Pathology meeting, the company is forging a global alliance with a leading US medical institution and other organizations to harness technology for ...

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...